CRISPR Gene Editing Congress, 25-27 February 2015 in Boston, MA

25-27 February 2015 | Boston, USA
Tel: +1 212 531 5898 | Email: info@hansonwade.com
RESEARCHED & DEVELOPED BY:
Unlocking Precision Genome Editing for
Therapeutic Development & Biomedical
Research Applications
GEORGE CHURCH
Harvard University
ALEXANDRA GLUCKSMANN
Editas Medicine
ERIC RHODES
Horizon Discovery
KEITH JOUNG
Harvard University
RODGER NOVAK
CRISPR Therapeutics
This is
designed to
describe the
profound
impact CRISPR
is having on
basic research
and therapeutic
development. It
will explore the
research tools,
bioinformatics
and expertise
needed to make
the most of this
breakthrough
technology
Eric Rhodes on
CRISPR Congress 2015
crispr-congress.com
LEAD PARTNER PROGRAM PARTNERS EXHIBITORHOSTING PARTNER

1 6
3 8
2 7
4 9
5 10
BENEFITS OF ATTENDING
Tel: +1 212 531 5898 Email: info@hansonwade.com
crispr-congress.com #CRISPR2015 CRISPR Precision Genome Editing
CRISPR Precision Gene Editing Congress
Boston, USA | 25-27 February 2015
Enhance the Implementation of CRISPR Gene
Editing Technology & Advance your Research
Seize the value of CRISPR/Cas9 gene editing and discover its evolving
application in target identification and therapeutic development
With its ground breaking convenience and simplicity, the
emergence of CRISPR genome technology has taken
gene editing from a niche pursuit and opened it up to
the wider scientific community, in turn revolutionizing
and optimizing the application of highly precise genome
editing.
Key industry leaders will gather at the inaugural CRISPR
Precision Gene Editing Congress with an ultimate
purpose of addressing the importance of overcoming
specificity, efficiency and delivery challenges associated
with the CRISPR/Cas9 system. Furthermore, pioneers
will showcase the exploding biomedical and therapeutic
potential of gene editing tools for drug discovery and
development.
CRISPR congress brings together those who are striving
to unlock the potential and capture the innovative
applications of CRISPR technology under one roof.
Utilize the industry’s greatest minds to optimize your
gene engineering applications.
Discover the approaches being applied to
overcome CRISPR/Cas9 off-cuts and enhance
specificity
Harness the bioinformatic approach to detect
off-cuts and improve CRISPR/Cas9 specificity
TOP 10 REASONS TO ATTEND CRISPR CONGRESS
Harness the innovative approaches being utilized
to overcome in vivo delivery challenges in the
development of disease models
Explore how CRISPR based functional
genomic screening is being applied to improve
identification and validation of new drug
targets
Explore how CRISPR technology is being
utilized in basic research to enhance your own
application of CRISPR gene editing
Discover how CRISPR technology is being
applied to compliment other gene editing tools
Learn about the application of CRISPR
technology in epigenome editing of human cells
and stem cell biology
Harness the high throughout methods being
developed for efficient RNA delivery and gene
editing
Enhance your knowledge on key safety issues
surrounding the development of CRISPR-based
therapeutics
Learn about the platform advancements
required to advance CRISPR technology to the
clinic and develop CRISPR-based therapies

SPEAKER FACULTY
Eric Rhodes
Chief Technology Officer
Horizon Discovery
Katrine Bosley
Chief Executive Officer
Editas Medicine
Keith Joung
Associate Chief of Pathology for
Research and the Jim and Ann
Orr MGH Research Scholar,
Massachusetts General Hospital;
Associate Professor of Pathology,
Harvard University
Alexandra Glucksmann
Chief Operating Officer
Editas Medicine
Matthew Porteus
Associate Professor of
Paediatrics
Stanford University
Charles Gersbach
Assistant Professor, Biomedical
Engineering, Investigator, Center
for Genomic and Computational
Biology
Duke University
Daniel Anderson
Sam Goldblith Associate
Professor
Massachusetts Institute
of Technology (MIT)
David Bumcrot
Senior Director, Molecular
and Cell Biology
Editas Medicine
Mark Kay
Professor of Pediatrics and
Genetics
Stanford University
Yi Yang
Senior Research Investigator
Novartis
Kiran Musunuru
Assistant Professor, Stem Cell
and Regenerative Biology
Harvard University
Stanley Qi
Assistant Professor,
Bioengineering and
Chemical and Systems
Biology
Stanford University
Gregory Davis
R&D Manager, Molecular
Biotechnology
Sigma-Aldrich
Corporation
Jason Potter
Senior Scientist in Protein
Engineering
Thermo Fisher Scientific
TJ Cradick
Director of Protein
Engineering Facility
Georgia Institute of
Technology
David Liu
Professor of Chemistry and
Chemical Biology, Howard
Hughes Medical Institute
Investigator
Harvard University
Wenning Qin
Associate Director of Genetic
Engineering Technologies
The Jackson Laboratory
Richard Chen
Principal Scientist, Genetics
and Pharmacogenomics
Merck
Rodger Novak
Chief Executive Officer
CRISPR Therapeutics
Terence Flotte
Professor, Dean
and Provost,
University of Massachusetts
Medical School
Derrick Rossi
Assistant Professor, Stem Cell and
Regenerative Biology
Harvard University
Christian Mueller
Assistant Professor,
Paediatrics
University of
Massachusetts
Medical School
John Feder
Associate Director of
Genome Biology
Bristol-Myers Squibb
Hari Jayaram
Senior Scientist
Editas Medicine
Jochen Welcker
Senior Manager Scientific
Development
Taconic Biosciences GmbH
VittorioSebastiano
AssistantProfessorofObstetrics
andGynecology,DirectorofHuman
PluripotentStemCellsCoreFacility
andTKTC
StanfordCancerInstitute
George Church
Professor of Genetics
Harvard Medical School

CONFERENCE DAY ONE
8.00 Registration, Breakfast & Networking
9.00 Welcome Address from Lead Partner Horizon Discovery Eric Rhodes, Chief Technology Officer, Horizon Discovery
9.05 Chair’s Opening Remarks
Alexandra Glucksmann, Chief Operating Officer,
Editas Medicine
9.10 Unlocking Future CRISPR Applications: Conversations
That Matter
Gain an exclusive insight into the latest developments within the field of CRISPR
technology via one-on-one interviews with a panel of key opinion leaders. Join those
paving the way in implementing CRISPR technology for therapeutic and biomedical
applications, as well as in drug discovery and development. The panel will discuss and
answer the following questions:
• Are we in a CRISPR revolution?
• What has been the impact so far and how high can CRISPR reach?
• How can we make this technology better and work harder?
• What are the potential applications of CRISPR in drug discovery and development?
• How is the technology being utilized for gene therapy?
Moderator: Alexandra Glucksmann, Chief Operating
Officer, Editas Medicine
Keith Joung, Associate Chief of Pathology for Research
and the Jim and Ann Orr MGH Research Scholar,
Massachusetts General Hospital; Associate Professor
of Pathology, Harvard University
Rodger Novak, Chief Executive Officer, CRISPR
Therapeutics
Charles Gersbach, Assistant Professor, Department of
Biomedical Engineering, Investigator, Center for Genomic
and Computational Biology, Co-Director, Center for
Biomolecular and Tissue Engineering, Duke University
Katrine Bosley, Chief Executive Officer, Editas Medicine
10.00 CRISPR and the Rapidly Changing Landscape of Genome
Editing
• Learnings accumulated from over 1 year of industrial application of CRISPR to
in vitro and in vivo genome editing. Incorporation of CRISPR into products, services
and research programs that enable customers engaged at every stage of the
healthcare continuum
• Harnessing gene editing of haplogenic cell lines
• A bioinformatics approach for CRISPR experimental design
Eric Rhodes, Chief Technology Officer, Horizon Discovery
Horizon welcome’s their partners:
Tilmann Burckstummer, Director Research and
Development, Horizon Genomics GmbH
Riley Doyle, Chief Executive Officer,
Desktop Genetics Ltd
10.30 Morning Refreshments & Speed Networking
Harnessing CRISPR Technology for Epigenome Editing
11.30 Optimizing Technologies for CRISPR-Based Targeted
Genome and Epigenome Editing of Human Cells
• Harness the latest advances in the technologies for highly efficient CRISPR-based
genome editing of human cells
• Learn about the innovative approaches in CRISPR-mediated epigenome editing of
human cells
Keith Joung, Associate Chief of Pathology for
Research and the Jim and Ann Orr MGH Research
Scholar, Massachusetts General Hospital; Associate
Professor of Pathology, Harvard University
12.30 Genome and Epigenome Modification with ZFNs and
CRISPR/Cas Systems
• CRISPR nuclease and highly specific paired nickase formats for genome editing in
animal and plant cells
• Donor DNA formats and their impact on DNA repair rates
• New experimental possibilities using lentiviral delivery of CRISPR elements and
CRISPR-based screening
• Zinc finger and CRISPR-mediated epigenetic modifications
Gregory Davis, R&D Manager, Molecular
Biotechnology, Sigma-Aldrich Corporation
1.00 Networking Lunch & Speakers’ Corner
2.00 Epigenome Editing and Controlling Cell Phenotype
• Utilizing CRISPR/Cas9-based epigenome editors which are exceptionally specific with
regards to genome-wide DNA-binding, gene regulation, and chromatin remodeling
• Discover how gene network activation by CRISPR/Cas9-based epigenome editors can
be used to reprogram cell phenotype and drive pluripotent cell differentiation
• Harness these enhanced strategies for disease modeling, drug screening and
potentially regenerative medicine
Charles Gersbach, Assistant Professor, Department
of Biomedical Engineering, Investigator, Center for
Genomic and Computational Biology, Co-Director,
Center for Biomolecular and Tissue Engineering, Duke
University
Wednesday 25th February 2015 Keynote Session Interactive Session Networking Session

The Discovery & Implementation of CRISPR Technology in Innovative Applications
2.30 Genome Editing Tools and Workflows to Address Cell
Engineering Needs
• Utilising the Cas9 protein or cas9 mRNA
• Cationic lipid mediated transfection or electroporation workflows
• Developing up to 95% single knock outs in difficult cell lines
• High efficiencies for bi-allelic multiplex knock out
Jason Potter, Senior Scientist in Protein Engineering,
3.00 Genome Editing to Dissect the Role of Retroviral lnCRNAs
in Human Development
• Overview of lncRNAs of retroviral origin in human and primates
• Role of lncRNAs in human pluripotent cells
• Genome editing in diverse embryonic cell types and functional characterization on
one specific lncRNA
Vittorio Sebastiano, Assistant Professor of Obstetrics
and Gynecology, Director of Human Pluripotent Stem
Cells Core Facility and Transgenic, Knockout and
Tumor Model Center (TKTC), Stanford Cancer Institute
3.30 Ultra-Sensitive Quantification of Genome Editing Events
by Droplet Digital PCR
• Genome editing events are rare, with NHEJ and HDR allele frequencies often <5%
in targeted cell populations
• Locus-specific quantification of NHEJ versus HDR alleles is emerging as an
important readout for optimizing genome-editing protocols
• Here we describe the use of droplet digital PCR (ddPCR) for ultra-sensitive
absolute quantification of NHEJ and HDR alleles in edited samples
Jennifer Berman , Staff Scientist, Applications, Digital
Biology Center, Bio-Rad Laboratories
4.00 Afternoon Refreshments & Poster Session
4.30 Technologies and Applications Enabled by CRISPR-
Mediated Gene Regulation
• Establishing technologies for targeted gene regulation using a nuclease deficient
CRISPR system
• Development of CRISPR technology for different goals of gene regulation such
as activation or repression, known as CRISPR interference (CRISPRi) or CRISPR
activation (CRISPRa)
• Applications of CRISPRi/a for drug target characterization, cell engineering, and
genome-wide screenings
Stanley Qi, Assistant Professor, Bioengineering and
Chemical and Systems Biology, Stanford University
5.00 Interactive CRISPR Mastermind
The CRISPR speaker faculty is second to none but there is just as much knowledge
in the audience as there is onstage. Tap into the wealth of perspectives on key issues
during interactive discussions, specifically designed so you can learn from fellow peers
and CRISPR experts. Drive your own learning, crowd-source ideas and get inspired!
1. What are the current approaches being utilized for enhancing CRISPR specificity -
overcoming off-target challenges?
2. How to overcome delivery challenges within genome editing
3. Utilizing CRISPR technology for modeling disease: How CRISPR technology
can be best applied to convert human GWAS/whole genome sequencing data from
“association” to “causation”?
4. How to use a bioinformatic approach for enhancing CRISPR applications
5. What challenges need to be addressed to establish safety models for gene therapy?
MODERATED BY:
Keith Joung, Associate Chief of Pathology for Research
and the Jim and Ann Orr MGH Research Scholar,
Massachusetts General Hospital; Associate Professor
of Pathology, Harvard University
David Liu, Professor of Chemistry and Chemical
Biology, Howard Hughes Medical Institute Investigator,
Harvard University
David Bumcrot, Senior Director, Molecular and Cell
Biology, Editas Medicine
Richard Chen, Principal Scientist, Genetics and
Pharmacogenomics, Merck
Matthew Porteus, Associate Professor of Paediatrics,
Stanford University
John Feder, Associate Director of Genome Biology,
Bristol-Myers Squibb
5.50 Chair’s Closing Remarks
Alexandra Glucksmann, Chief Operating Officer,
Editas Medicine
6.00 Close of Day 1
6.10 Evening Drinks Reception Hosted by Horizon Discovery
Keynote Session Interactive Session Networking Session
CONFERENCE DAY ONE - CONTINUED
Wednesday 25th February 2015

CONFERENCE DAY TWO
8.00 Breakfast & Networking
9.00 Chair’s Opening Remarks
CRISPR State of Address- What can we take forward from the discussions so far?
Overcoming the Main CRISPR Technology Hurdles: Specificity & Delivery
9.10 Nucleic Acid Delivery Systems for RNA Therapy and Gene
Editing
• To discuss the high throughput methods for developing and characterizing RNA
delivery and gene editing systems
• Developing delivery formulations with in vivo efficacy, and show potential
therapeutic application for the treatment of genetic disease, viral infection, and
cancer
Daniel Anderson, Sam Goldblith Associate Professor,
Massachusetts Institute of Technology (MIT)
9.40 Bioinformatics for Testing and Improving CRISPR
Specificity
• Harnessing bioinformatics for the determination of possible off-target cleavage
sites
• Developing assays for off-target cleavage events
TJ Cradick, Director of Protein Engineering Facility,
Georgia Institute of Technology
10.10 From “Gene Editing” to True Genome-Scale
Engineering”
• Reducing issues with competing events like Non-Homologous End-Joining
(NHEJ) and efficiency of large construct insertion/replacements in homologous
recombination editing
• Overcoming NHEJ events with the use of a promising alternative to double-strand
breaks (CRISPR, dual nickase or FokI) via recombinase/integrase mechanisms
George Church, Professor of Genetics, Harvard
Medical School
10.40 Morning Refreshments & Networking
11.00 Increasing the Therapeutic Relevance of CRISPR
Technologies to Address Delivery and Specificity
Challenges
• Discover the successful engineering of TALEN and Cas9 variants with greatly
improved specificity
• Harness a new approach to the delivery of proteins that has enabled the highly
potent, non-endosomal delivery of genome-editing proteins into mammalian cells
David Liu, Professor of Chemistry and Chemical
Biology, Howard Hughes Medical Institute Investigator,
Harvard University
12.00 Bioinformatic Approaches to Optimize Guide-RNA Design
and Assay Cas9 Specificity
• Explore the various algorithms and tools to assist in design of guide-RNAs for
Cas9 mediated gene editing
• Explore formats to standardize reporting of CRISPR mediated gene editing
experiments
Hari Jayaram, Senior Scientist, Editas Medicine
12.30 Networking Lunch
Application of CRISPR in Disease Modeling & Drug Screening
1.30 Interrogation of Novel Genes and Loci in Cardiovascular
Diseases with CRISPR Genome Editing
• Utilizing CRISPR to interrogate novel genes identified by genomic studies of
cardiovascular disease
• Implementing CRISPR to generate reporter cell lines for functional and drug
screens
Kiran Musunuru, Assistant Professor, Stem Cell and
Regenerative Biology, Harvard University
2.00 CRISPR/Cas-Mediated Genome Engineering in Mice with
High Efficiency and Throughput
• Significantly improving the efficiency of CRISPR/Cas-mediated insertion of a
transgene into an endogenous locus through pronuclear injection into zygotes
• Using whole genome sequencing to comprehensively characterized the off-target
effect of CRISPR/Cas9 targeting the Nanog locus
Wenning Qin, Associate Director of Genetic
Engineering Technologies, The Jackson Laboratory
Thursday 26th February 2015 Keynote Session Interactive Session Networking Session

2.30 Therapeutic Genome Editing in Human Hematopoietic
Stem Cells using CRISPR/Cas9 Technology
• Harnessing CRISPR/Cas9 technology for applying genome editing in human
hematopoietic stem cells
• How the CRISPR/Cas9 system can be used to achieve very high on-target and very
low off-target mutagenesis in human CD34+ human hematopoietic stem cells
Derrick Rossi, Assistant Professor, Stem Cell and
Regenerative Biology, Harvard University
3.00 Rapid Generation of Mouse and Rat Mutants by CRISPR/
Cas in One-Cell Embryos
• Experiences from the implementation of CRISPR/Cas-technology to routine model
generation
• Generation of knock-in- and conditional knock-out alleles
• Tailoring and refining existing humanized mouse models
Jochen Welcker, Senior Manager Scientific
Development, Taconic Biosciences
3.30 A CRISPR Way for Drug Discovery
• Harnessing CRISPR technology for target validation and for identifying target of
compound
Yi Yang, Senior Research Investigator, Novartis
4.00 Afternoon Refreshments
Advances in Genome Editing Technologies for Precision Gene Therapy
4.30 Developing a Combination of Genome Editing
Technologies to Enhance Application Specific Genetic
Engineering
• Understand the advantages and disadvantages of the different nuclease platforms
that are currently available and what criteria one might use to choose
• Opportunities and challenges present in translating genome editing to future
therapeutics
Matthew Porteus, Associate Professor of Paediatrics,
Stanford University
5.00 Alpha-1 Antitrypsin Deficiency Liver Disease: Genome
Editing for Animal Models and Gene Therapy
• Summary of animal model creation and potential selective advantage of correction
of AAT liver disease
• In vivo proof if concept for gene transfer, gene silencing and genome editing in
AAT liver disease
Using Genome Editing to Create a Knockout Mouse for
Alpha-1 anti Trypsin and Modify Hepatocytes for Stem
Cell Therapy
• Methods developed for knocking out 5 tandem repeats of the serpina1 gene in
mice
• Editing hepatocytes to increase their secretion of alpha 1 antitrypsin
Terence Flotte, Professor, Dean and Provost,
University of Massachusetts Medical School
Christian Mueller, Assistant Professor, Paediatrics,
University of Massachusetts Medical School
5.30 Therapeutic Promoterless Gene Targeting Without
Nucleases
• Provide a general understanding of rAAV-based gene therapeutics including
current successes and limitations in a clinical setting
• Discuss the proof-of-concept studies to support therapeutic application of
promoter less genome editing using rAAV vectors
Mark Kay, Professor of Pediatrics and Genetic,
Stanford University
6.00 Concluding Objectives for CRISPR Community – What’s
on the Horizon?
6.05 Close of Congress
6.10 Evening Drinks Reception Hosted by Sigma-Aldrich
CONFERENCE DAY TWO - CONTINUED
Thursday 26th February 2015 Keynote Session Interactive Session Networking Session

WORKSHOP A
WORKSHOP B
During this 3 hour interactive workshop, you will learn:
• What indications are addressable by current CRISPR technology?
• What platform advancements are necessary to significantly broaden the range of
CRISPR-based therapeutics?
• What are the key safety issues for clinical development of CRISPR technology?
During this 3 hour interactive workshop, you will learn:
• The main challenges surrounding CRISPR specificity
• The latest efforts in the field to define off-target effects of CRISPR-Cas nucleases
• What approaches need to be harnessed to improve CRISPR-Cas nuclease specificities of action
in human cells
Dr. David Bumcrot is Senior Director of Molecular & Cell Biology at Editas Medicine, Inc.
During his 18 year career he has held positions at a number of innovative biotechnology
companies developing novel therapeutic technologies. Prior to Editas, he was a Director of
Research at Alnylam Pharmaceuticals where he worked to advance several novel RNAi-
based drugs into clinical testing.
Workshop Leader
David Bumcrot
Senior Director, Molecular and Cell
Biology
Editas Medicine
Advancing CRISPR Technology into the Clinic
Date: Friday 27th February 2015 | Time: 9.00am – 12.00pm
Exploring Innovative Approaches: Defining and
Improving the Specificities of CRISPR-Cas Nucleases
Date: Friday 27th February 2015 | Time: 1.00pm – 4.00pm
Workshop Leader
Keith Joung
Associate Chief of Pathology for Research and the Jim
and Ann Orr MGH Research Scholar
Massachusetts General Hospital
Associate Professor of Pathology
Harvard University
J. Keith Joung is a leading innovator in the field of genome editing. Dr. Joung has been a pioneer in the development of important
technologies for targeted genome editing and epigenome editing of human cells. He is a scientific co-founder of Editas Medicine, a company
dedicated to the translation of genome editing technologies for therapy of human diseases.

SPONSORS
Sigma-Aldrich
Sigma-Aldrich is proud to offer its newest line of genome editing tools,
Sigma CRISPRs, to the global research community. Sigma CRISPRs offer
rapid, reliable and reproducible results – everything you need for gene
editing experiments. Sigma-Aldrich also offers the CRISPR Core Partnership
Program providing scientists and core facilities with world class service
and a diverse portfolio of innovative CRISPR reagents, with the support of
an industry-leading bioinformatics engine. The Cell Design Studio team at
Sigma Aldrich, utilizes CRISPR, ZFN, and shRNA technologies to rapidly and
efficiently generate model cell lines to be used in basic research, cell-based
assays, target validation and much more.
www.sigmaaldrich.com
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving
science, our mission is to enable our customers to make the world healthier,
cleaner and safer. We help our customers accelerate life Sciences research,
solve complex analytical challenges, improve patient diagnostics and increase
laboratory productivity. Through our four premier brands Thermo Scientific,
Life Technologies, Fisher Scientific and Unity Lab Services we offer an
unmatched combination of innovative technologies, purchasing convenience
and comprehensive support.
www.thermoscientific.com
HOSTING PARTNER
PROGRAM PARTNER
The Jackson Laboratory
The Jackson Laboratory is an independent, nonprofit biomedical research
institution and a National Cancer Institute-designated Cancer Center with
more than 1,500 employees. Headquartered in Bar Harbor, Maine, it has
a facility in Sacramento, Calif., and a new genomic medicine institute in
Farmington, Conn. The Laboratory’s mission is to discover precise genomic
solutions for disease and empower the global biomedical community in the
shared quest to improve human health.
www.jax.org
PROGRAM PARTNER
Horizon Discovery
Horizon Discovery combines long scientific heritage in translational
research with GENESIS™, a precision gene editing platform incorporating
rAAV, CRISPR and ZFN technologies. Horizon supplies genetically-defined
cell lines, gene-editing tools and services, custom cell line generation,
molecular reference standards, and contract research services to
approaching 1,000 academic, clinical and biopharmaceutical organisations.
www.horizondiscovery.com
LEAD PARTNER

SPONSORS
Bio-Rad
Bio-Rad Laboratories, Inc. designs, manufactures, and distributes
a broad range of innovative tools and services to the life science
research and clinical diagnostics markets. Founded in 1952, Bio-
Rad has a global team of more than 7,750 employees and serves
more than 100,000 research and industry customers worldwide
through the company’s global network of operations. Throughout
its existence, Bio-Rad has built strong customer relationships that
advance scientific research and development efforts and support
the introduction of new technology used in the growing fields of
genomics, proteomics, drug discovery, food safety, and medical
diagnostics.
www.bio-rad.com
PROGRAM PARTNER
Transposagen
Transposagen is a worldwide leader in genome engineering
technologies and services with applications in therapeutics,
research & drug discovery, bioproduction, clinical genetic testing
and agriculture. Our products and services include Footprint-
Free(tm) Gene Editing, NextGEN(tm) CRISPR, XTN(tm) TALENs,
and custom cell lines, stem cells, and animal models. Our unique
genome engineering capabilities allow for the creation of nearly
any genetic modification in any genome.
www.transposagenbio.com
EXHIBITOR
Taconic
Taconic is a leading provider of life sciences solutions to
researchers worldwide, offering innovative animal models and
scientific services that facilitate in vivo studies and advance drug
discovery. Our solutions enable investigators to obtain reliable data
early in the development cycle - reducing costs, accelerating time-
to-market, and creating a strong competitive advantage.
tONCO(TM) allows easy access to a comprehensive portfolio of
translational rodent models and services covering every stage of
preclinical in vivo oncology research.
www.taconic.com
PROGRAM PARTNER

Code:5164
* All discount offers (including team discounts) require payment at the time of registration to receive any discount. ‘Early Bird’ discounts require
payment at time of registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer.
The conference fee includes lunch, refreshments and course documentation. The fee does not include travel or hotel accommodation.
Full payment is due on registration. Cancellation and Substitution
Policy: Cancellations must be received in writing. If the cancellation
is received more than 14 days before the conference attendees will
receive a full credit to a future conference. Cancellations received
14 days or less (including the fourteenth day) prior to the conference
will be liable for the full fee. A substitution from the same
organisation can be made at any time.
Changes to Conference & Agenda: Hanson Wade reserves the right
to postpone or cancel an event, to change the location or alter the
advertised speakers. Hanson Wade is not responsible for any loss
or damage or costs incurred as a result of substitution, alteration,
postponement or cancellation of an event for any reason and
including causes beyond its control including without limitation, acts
of God, natural disasters, sabotage, accident, trade or industrial
disputes, terrorism or hostilities.
Data Protection: The personal information shown and/or provided by
you will be held in a database. It may be used to keep you up to date
with developments in your industry. Sometimes your details may be
obtained or made available to third parties for marketing purposes.
If you do not wish your details to be used for this purpose, please
write to: Database Manager, Hanson Wade, 4th Floor, 52 Grosvenor
Gardens, London, SW1W 0AU
Hanson Wade Limited. Registered in England & Wales. Company
No: 6752216
TERMS & CONDITIONS
VENUE AND ACCOMMODATION:
REGISTER
EVENT PRICES
PRICING & VENUE
INDUSTRY*
Package Standard Prices
GOLD PACKAGE:
Conference + 2 Workshops
$3797 (save $200)
SILVER PACKAGE:
Conference + 1 Workshop
$3198 (save $100)
BRONZE PACKAGE:
Conference Only
$2599
Workshops (each) $699
ACADEMIC*
Package Standard Prices
GOLD PACKAGE:
Conference + 2 Workshops
$2397 (save $200)
SILVER PACKAGE:
Conference + 1 Workshop
$1998 (save $100)
BRONZE PACKAGE:
Conference Only
$1599
Workshops (each) $499
Venue: Located on the Cambridge side of
the Charles River, the newly renovated Royal
Sonesta Boston is a AAA approved Four Diamond
upscale hotel offering guests spectacular city
views, luxury accommodations, regional cuisine,
and contemporary art.
For the traveler looking to experience the best
Boston has to offer, there are many shops,
museums, and historical sites conveniently located
near the Royal Sonesta Boston, known as one
of the best Boston luxury hotels. The hotel also
offers weekday SUV service to the Cambridge area.
Hotel name
Royal Sonesta
40 Edwin Land Boulevard
Cambridge, MA 02142 USA
Accommodation: Overnight
accommodation is not
included in the registration
fee, however accommodation
options will be sent out with
your confirmation email upon
registering.
crispr-congress.com/register
Tel: +1 212 531 5898
Email: register@hansonwade.com
Mail:
Hanson Wade
4th Floor, 52 Grosvenor Gardens,
London, SW1W 0AU
• 10% discount – 3 delegates
• 15% discount – 4 delegates
• 20% discount – 5 or more delegates
Please note that discounts are only valid when
three or more delegates from one company book
and pay at the same time.
TEAM DISCOUNTS*

CRISPR Gene Editing Congress, 25-27 February 2015 in Boston, MA

Recommandé

Recommandé

Contenu connexe

Tendances

Tendances (20)

En vedette

En vedette (12)

Similaire à CRISPR Gene Editing Congress, 25-27 February 2015 in Boston, MA

Similaire à CRISPR Gene Editing Congress, 25-27 February 2015 in Boston, MA (20)

Plus de Diane McKenna

Plus de Diane McKenna (7)

Dernier

Dernier (20)

CRISPR Gene Editing Congress, 25-27 February 2015 in Boston, MA